• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

    11.94 +0.90 (+8.15%)
    Streaming Delayed Price Updated: 3:50 PM EDT, Apr 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 24,370
    Open 11.26
    Bid (Size) 11.39 (100)
    Ask (Size) 11.98 (200)
    Prev. Close 11.04
    Today's Range 10.90 - 11.95
    52wk Range 6.340 - 76.00
    Shares Outstanding 34,422,063
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
    From MiNK Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    +7.4%
    +7.4%
    1 Month
    +22.6%
    +22.6%
    3 Month
    -0.5%
    -0.5%
    6 Month
    -15.3%
    -15.3%
    1 Year
    +57.9%
    +57.9%

    More News

    Read More
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
    From MiNK Therapeutics
    Via GlobeNewswire
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    What's going on in today's pre-market session ↗
    Via Chartmill
    Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
    Via Chartmill
    News headline image
    Why Did INKT Stock Surge 70% In Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics (INKT) Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 14, 2025 ↗
    Via Benzinga
    News headline image
    MiNK Therapeutics's Earnings Outlook ↗
    Via Benzinga
    News headline image
    MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Extends Cash Runway ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is MiNK Therapeutics, Inc. - Common Stock publicly traded?
    Yes, MiNK Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does MiNK Therapeutics, Inc. - Common Stock trade on?
    MiNK Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MiNK Therapeutics, Inc. - Common Stock?
    The ticker symbol for MiNK Therapeutics, Inc. - Common Stock is INKT on the Nasdaq Stock Market
    What is the current price of MiNK Therapeutics, Inc. - Common Stock?
    The current price of MiNK Therapeutics, Inc. - Common Stock is 11.94
    When was MiNK Therapeutics, Inc. - Common Stock last traded?
    The last trade of MiNK Therapeutics, Inc. - Common Stock was at 04/13/26 03:50 PM ET
    What is the market capitalization of MiNK Therapeutics, Inc. - Common Stock?
    The market capitalization of MiNK Therapeutics, Inc. - Common Stock is 411.00M
    How many shares of MiNK Therapeutics, Inc. - Common Stock are outstanding?
    MiNK Therapeutics, Inc. - Common Stock has 411M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.